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This journal is © The Royal Society of CFluorinated beta-sheet breaker peptides
Joana A. Loureiro,a Rosa Crespo,b Hans Bo¨rner,c Pedro M. Martins,ab
Fernando A. Rocha,a Manuel Coelho,a M. Carmo Pereira*a and Sandra Rocha*d
The aggregation of amyloid-b peptide (Ab) has been linked to the formation of neuritic plaques, which are
pathological hallmarks of Alzheimer's disease. We synthesized peptides containing ﬂuorinated amino acids
and studied their eﬀect on the Ab aggregation. The peptides were based on the sequence LVFFD, in which
valine was substituted by either 4,4,4-triﬂuorovaline or 4-ﬂuoroproline, or the phenylalanine at position 3
was replaced by 3,4,5-triﬂuorophenylalanine. Our results demonstrate that ﬂuorination of the
hydrophobic residue valine or phenylalanine is eﬀective in preventing the Ab aggregation. This study
opens up the possibility of using new sequences based on ﬂuorinated amino acids to inhibit the
amyloid-ﬁbril formation.Introduction
Amyloid b-peptide (Ab) is about 4 kDa and it accumulates
extracellularly in the brain as amyloid brils, which form the
dense aggregates – neuritic plaques – that pathologically char-
acterize Alzheimer's disease (AD).1 The aggregation process of
Ab is described as a nucleation process, with the formation of
unstable intermediates that act as seeds. At least two interme-
diates have been identied during amyloid bril formation:
intermediates that are soluble and of low molecular weight,
composed of dimeric or oligomeric peptide molecules, and the
protobrils that are short and exible brils.2
Increasing evidence suggests that soluble Ab oligomers
might be critical for the onset of AD.3–7 In the view of this
hypothesis, a possible strategy to treat the disease is to inhibit
the early stages of Ab aggregation.8 The two hydrophobic cores
of Ab, the residues 17–21 and 30–42, have been associated with
the peptide aggregation.9,10 Soto et al. designed a short peptide,
based on the 17–21 hydrophobic core of Ab (LVFFA), which
binds to the full length Ab and prevents its aggregation.11 This
inhibitor has a similar degree of hydrophobicity to that of the
17–21 core but it has a very low propensity to adopt a b-sheet
conformation due to the presence of a proline residue. Valine,
which is considered a key residue for the b-sheet formation, was
replaced by proline and alanine was substituted by aspartic
acid to improve the peptide solubility.11–13 The sequence LPFFD,ing, Faculty of Engineering, University of
pt
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hemistry 2014referred to as iAb5, binds to Ab and blocks the Ab–Ab molecule
interactions, inhibiting the formation of amyloid brils.
Certain uorinated compounds have also been proposed as
inhibitors of the Ab aggregation.14–16 Fluorinated solvents such
as hexauoroisopropanol induce an a-helix structure in Ab
peptide. A similar eﬀect is observed when Ab interacts with
poly(tetrauoroethylene) surfaces or uorinated nano-
particles.17–19 Since the hydrogenated analogues of the nano-
particles were not able to prevent the amyloid bril formation,
it has been postulated that uorine atoms play an important
role in the inhibition of Ab aggregation. We have thus synthe-
sized peptides containing uorinated amino acids and studied
their inuence on Ab oligomerization. The uorinated peptides
are also based on the hydrophobic central residues of Ab(1–42)
17–21 (LVFFA) and on the iAb5 beta-sheet breaker peptide. The
aim is to study the impact of uorine atoms on the beta-sheet
breaker property of short peptide sequences and to understand
the role of uorine atoms on the Ab(1–42) aggregation. The
uorinated sequences were covalently linked to polyethylene
glycol (PEG) to increase their solubility (Fig. 1). We previously
showed that coupling iAb5 to PEG does not compromise its
aﬃnity to Ab or the iAb5 beta-sheet breaker activity.20 PEG has
relatively low toxicity and is known to reduce proteolytic
degradation.21 The use of non-natural residues such as uori-
nated amino acids is also described to eﬃciently improve the
stability of peptides or proteins against enzymatic degrada-
tion.22 The conjugates of uorinated peptide–PEG were char-
acterized by matrix-assisted laser desorption/ionization mass
spectrometry. The kinetics of Ab(1–42) aggregation, in the pres-
ence of the conjugates, were evaluated by the thioavin T assay
and the data were tted using the crystallization-like model
recently described by Crespo et al.23 The ultrastructure char-
acterization of the Ab aggregates was performed by trans-
mission electron microscopy.J. Mater. Chem. B, 2014, 2, 2259–2264 | 2259
Fig. 1 Sequences of the amyloid-b peptide (1–42) and the ﬂuorinated
peptides conjugated to polyethylene glycol (PEG) used in this study.
The chemical structure of the ﬂuorinated amino acids is also shown
(source: PubChem of the National Center for Biotechnology
Information).
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View Article OnlineMaterial and methods
Synthesis of conjugates of uorinated peptides and
polyethylene glycol
The conjugates were prepared by the solid-phase supported
strategy. Direct synthesis of the conjugate was performed
applying a resin comprising a cleavable PEG spacer. Automated
stepwise amino acid attachment was applied, following stan-
dard Fmoc-protocols. TentaGel PEG Attached Peptide resin
(loading: 0.24 mmol g1; Mn ¼ 3200, PDI ¼ 1.06 [GPC (THF,
calibrated against linear PEG3200 standards, PSS, Germany)])
was purchased from Rapp, Polymere GmbH. Fmoc amino acid
derivatives (Fmoc–phenylalanine OH, Fmoc–leucine OH,
Fmoc–aspartic acid OH, Fmoc–valine OH, Fmoc–4,4,4-tri-
uoro-D,L-valine, Fmoc–3,4,5-triuoro-L-phenylalanine and
Fmoc–trans-4-uoro-L-proline) were used as purchased from
AnaSpec. The sequences of the uorinated peptides are shown
in Fig. 1. Aer the synthesis, the conjugates were dissolved in
distilled water with 1% guanidinium hydrochloride and the pH
was adjusted to 7 with 1 M sodium hydroxide. The samples
were dialyzed against ultrapure water using a regenerate
cellulose membrane (MWCO 1000 Da) for 4 days followed by
lyophilization.Stock solutions of amyloid-b peptide
Ab(1–42) (amyloid-b peptide 1–42, purity > 95.22%, MW: 4514.14,
Selleck Chemicals) was dissolved in HFIP (1,1,1,3,3,3-hexa-
uoro-2-propanol, $99.8%, Sigma-Aldrich) at a concentration
of 1.0 mg mL1. HFIP was evaporated with nitrogen ow and
the peptide lm was dissolved in DMSO (dimethyl sulfoxide for
molecular biology, $99.9%, FW: 78.13, Sigma-Aldrich) at a
concentration of 9.0 mg mL1.2260 | J. Mater. Chem. B, 2014, 2, 2259–2264Matrix-assisted laser desorption/ionization mass
spectrometry (MALDI-TOF)
MALDI-TOF-MS measurements were performed using a
Voyager-DE STR BioSpectrometry Workstation MALDI-TOF
mass spectrometer (Perceptive Biosystems, Inc., Framingham,
MA, USA) at an acceleration voltage of 20 kV. The uorinated
peptide–PEG conjugates were dissolved in 0.1% TFA in aceto-
nitrile–water (1 : 1, v/v) at a concentration of 0.1 mg mL1. One
microliter of the analyte solution was mixed with l mL of an
alpha-cyano-4-hydroxycinnamic acid matrix solution consisting
of 10 mg of the matrix dissolved in 1 mL of 0.1% TFA in
acetonitrile–water (1 : 1, v/v). From the resulting mixture, 1 mL
was applied to the sample plate. Samples were air-dried at
room temperature (25 C). Each spectrum is a mean of 250 laser
shots.Thioavin T (ThT) binding assay
For kinetic studies, Ab(1–42) peptide (12.5 mM) was incubated at
37 C in 96 well plates (Nunclon Delta Surface) with the uori-
nated peptide–PEG conjugates (250 mM) in the presence of ThT
(0.7 mg mL1) in a PBS buﬀer. The ThT solution was ltered
using a 0.2 mm syringe lter before adding to the Ab samples.
The brils conjugated with ThT have the excitationmaximum at
450 nm and enhanced emission at 482 nm.24 The uorescence
intensity was measured every 30 minutes during 24 hours using
a Biotek Synergy 2 uorescence spectrometer with the excitation
lter at 420/50 nm and the emission lter at 485/20 nm. Stu-
dent's t-test statistical analysis was used to determine statistical
signicance between Ab(1–42) incubated alone and Ab(1–42)
incubated with conjugates (n $ 3).Theoretical crystallization-like model
The crystallization-like model (CLM) is a generic two-parameter
model that describes protein aggregation kinetics by a sequence
of nucleation and growth steps. The CLM is represented by the
following equation, in which a represents the normalized
fraction of amyloid protein converted into brils.
a ¼ 1 1
kb½expðkatÞ  1 þ 1 (1)
and ka and kb are the growth and the nucleation-to-growth rate
constants. The two parameters are related to the time required
to reach half of the total bril conversion (t50) and to the
aggregation rate (v50) given the slope of the a(t) curve at that
instant.Transmission electron microscopy (TEM)
The Ab(1–42) peptide (100 mM) was incubated at 37 C with each
of the uorinated peptide–PEG conjugates (2 mM) in a PBS
buﬀer (10 mM, pH: 7.4), for 48 hours. An aliquot of each sample
(5 mL) was placed on carbon–formvar coated 200–400 mesh
spacing grids and let to adsorb for ve minutes. The negative
staining was performed with a 2% ltered aqueous solution of
uranyl acetate for 45 seconds. The grids were visualized using a
Jeol JEM 1400 electron microscope at 80 kV.This journal is © The Royal Society of Chemistry 2014
Fig. 3 Fluorescence intensity of thioﬂavin T in Ab(1–42) samples con-
taining ﬂuorinated peptide–PEG conjugates incubated at 37 C. The
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View Article OnlineResults
Fluorinated peptide–PEG conjugates
The uorinated sequences conjugated to PEG were analysed by
MALDI-TOF-MS. The spectrum of LPfFFD–PEG is depicted as
representative of the results acquired for the conjugates and
shows the typical distribution of the polymer PEG with the
characteristic repeat unit of 44.1  0.5 Da, which could be
assigned to the ethylene oxide (EO) monomer of the PEG
(Fig. 2). The experimentally found signal at m/z 3694.8, for
example, can be assigned to [M + K]¼ 3692.3 Da by assuming an
M[EO] of 44.05 Da, n¼ 68 units, a mass of the peptideM[peptide]¼
655.8 Da, a mass of the polymer end groups 1H ¼ 1 Da and the
mass of a potassium counter ion M[counter ion] ¼ 39.1 Da.ﬂuorescence signal was normalized to the maximum intensity of the
sample of Ab(1–42) without conjugates. *Signiﬁcantly diﬀerent from the
Ab(1–42) control sample (p < 0.01).
Fig. 4 Numerical ﬁt (solid lines) of eqn (1) to the kinetic results of the
Ab(1–42) peptide incubated at 37 C in PBS buﬀer in the absence (C)
and in the presence of LPfFFD–PEG (D), LVFfFD–PEG (,), and LVfFFD–
PEG (B) conjugates, monitored by ThT ﬂuorescence. The Ab(1–42)
concentration was kept constant at 12.5 mM and the molar ratio of
Ab(1–42) : conjugates was 1 : 20. The aggregation rate (v50) was
obtained by ﬁtting a sigmoidal function to each kinetic trace according
to eqn (1).Impact of the peptide–PEG conjugates on Ab(1–42)
brillization
The aggregation of Ab(1–42) incubated at 37 C with LPfFFD–PEG,
LVFfFD–PEG and LVfFFD–PEG at a molar ratio of 1 : 20 was
evaluated by the ThT binding assay (Fig. 3 and 4). At 15 minutes
incubation time, the ThT uorescence intensity is low for all
samples, which indicates low content of amyloid brils. Aer
two hours, a large increase in the uorescence intensity is
observed for Ab(1–42) alone and for the Ab(1–42):LPfFFD–PEG
samples, reaching the maximum at 4 hour incubation time (the
uorescence intensities were normalized to that of Ab(1–42)
incubated with ThT at 37 C for 24 hours). The uorescence of
ThT in the presence of Ab(1–42) and LVFfFD–PEG showed only a
moderated increase (53%) aer 4 hours, whereas that of the
sample Ab(1–42):LVfFFD–PEG remained low (15%). The conju-
gates in the absence of Ab(1–42) do not induce any change in the
uorescence signal of ThT.
The kinetic data were tted according to the recently
proposed CLM model (Fig. 4). The time at half bril conversion
(t50) and the aggregation rate (v50) were obtained by tting a
sigmoidal function to each kinetic trace according to the CLM
(Table 1).23 In the case of sigmoidal-type aggregation kinetics
such as those represented in Fig. 4, v50 is solely dictated by the
growth rate constant ka. The parameter v50 did not change
signicantly in the presence of the conjugates. A marked
increase in the value of t50 is, however, evident for theFig. 2 MALDI-TOF-MS of a LPfFFD–PEG conjugate.
This journal is © The Royal Society of Chemistry 2014LVFfFD–PEG and LVfFFD–PEG, which can be explained by the
CLM as the result of either nucleation-prevention or solubility-
change eﬀects. The latter hypothesis is discarded by the fact
that the maximum uorescence signal did not show signicant
variation in the presence of conjugates. Therefore, we ascribe
the increased induction times to the inhibition of the nucle-
ation step as a possible consequence of the stabilization of the
Ab molecule by the conjugates. The higher value of the induc-
tion time t50 is obtained for the conjugate containing the uo-
rinated valine (LVfFFD–PEG), suggesting a stronger inhibitory
eﬀect in this case. Inhibitors of the amyloid bril formationmay
act upon the initial assembly of macromolecules forming the
stable nuclei (nucleation step) or block the subsequent additionJ. Mater. Chem. B, 2014, 2, 2259–2264 | 2261
Table 1 Time required to reach half of the total ﬁbril conversion (t50)
and delay in the aggregation of Ab(1–42) in the absence and the pres-
ence of ﬂuorinated peptide conjugates and LPFFD sequence
t50 (hours)
Delay in aggregation
(hours)
Ab(1–42) alone 2.1 —
Ab(1–42) and LPfFFD–PEG 2.4 0.2
Ab(1–42) and LVFfFD–PEG 3.6 1.5
Ab(1–42) and LVfFFD–PEG 5.2 3.1
Ab(1–42) and iAb5 5.4 3.3
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View Article Onlineof new growth units (growth step).23 A third way of action
involves the alteration of the thermodynamic solubility of the
polypeptide. This alternative is more unlikely to result in vivo
since cell and tissue media are in general buﬀered against non-
specic interactions. Compared to the eﬀect of a well-known
and well accepted beta-sheet breaker peptide, iAb5 (LPFFD), on
Ab(1–42) aggregation, a similar eﬀect was obtained by the
LVfFFD–PEG conjugate (3.1 hours) (Table 1). At the same molar
ratio and with the same Ab(1–42) batch, the reduction of the
aggregation time of Ab(1–42) is similar for iAb5 and LVfFFD–PEG.
The conjugate containing uorinated phenylalanine (LVFfFD–
PEG) induced an inhibitory eﬀect of 1.5 hours and the LPfFFD–
PEG did not inhibit the Ab(1–42) aggregation.
The Ab(1–42) : conjugate molar ratio of 1 : 5 did not signi-
cantly change the aggregation parameters of Ab, which
indicates that there is a threshold concentration for the
Ab–conjugate interactions.
TEM analysis showed that Ab(1–42) incubation at 37 C for 48
hours resulted in amyloid-like, unbranched brils (Fig. 5).
Ab(1–42) also formed brils in the presence of the conjugates (or
iAb5), although the samples containing LVFfFD–PEG and
LVfFFD–PEG show also small aggregates. This analysisFig. 5 TEM images of Ab(1–42) immediately after preparation (0 h) and
incubation for 48 h at 37 C in the absence and the presence of iAb5
(LPFFD), pegylated iAb5, ﬂuorinated peptide–PEG conjugates or PEG
(molar ratio of 1 : 20). The scale bar corresponds to 200 nm.
2262 | J. Mater. Chem. B, 2014, 2, 2259–2264demonstrates that the bioconjugates and the beta-sheet breaker
iAb5 are only delaying the Ab(1–42) brillogenesis.
Discussion
Ab(1–42) is an amphipathic peptide, which self-associates into
oligomers that are toxic to cells.25 The peptide aggregation
eventually leads to the formation of amyloid brils, which are
known to bind to Congo red and thioavin T dyes. The oligo-
merization and aggregation of Ab(1–42) are diﬃcult to control
and although many attempts have been made to nd a way to
inhibit these processes, the understanding of how diﬀerent
factors can contribute to their initiation is still puzzling. The
study on the self-assembly and structural transformation of
other amyloid-bril-forming peptides will provide important
insights into the understanding of the bril formation process
and to nd ways to prevent it.26–28
We relied on the knowledge that uorine atoms seem to
play a role in the prevention of Ab(1–42) aggregation and
developed peptides with uorinated amino acids to screen for
brillization inhibitors. The ThT assay evidenced that two of
the uorinated peptides (LVFfFD–PEG and LVfFFD–PEG) are
able to delay the aggregation of the Ab(1–42). Hydrophobic
interactions and H-bonding among side-chain groups are the
two major driving forces that control protein aggregation.29 A
large amount of evidence indicates that there are three distinct
regions within the Ab(1–42) sequence that might be involved in
its aggregation: the central hydrophobic cluster corresponding
to the 17–21 region, the 23–28 residues and the hydrophobic
C-terminus.30–32 Considering that uorine atoms increase the
hydrophobicity of the sequences, it is expected that they would
interact with the hydrophobic regions of Ab(1–42) to be segre-
gated away from the water. This interaction might contribute
to the prevention of Ab molecules to interact with each other,
thus inhibiting their aggregation. The PEG molecules linked to
the uorinated peptides can also contribute to the interactions
of the conjugates with Ab(1–42). We have previously shown that
the pegylation of a beta-sheet breaker peptide did not signi-
cantly change its binding to Ab(1–42).20 PEG is described to bind
to proteins such as albumin and lysozyme even in solution
with an ionic strength similar to the physiological conditions.33
In the case of the uorinated peptide–PEG conjugates, their
eﬀect on Ab(1–42) cannot be simply explained by PEG and Ab
interactions since the three conjugates show diﬀerent
outcomes.
The uorinated amino acids of the conjugates may play an
important role in delaying the Ab(1–42) aggregation by interact-
ing with the hydrophobic residues of the peptide. There is also a
geometric preference for the interactions between the C–F bond
and the side-chain amides of glutamine (E) 15 and asparagine
(N) 27 residues.34 Therefore, the uorine atoms might be able to
interact with the two stretches of Ab hydrophobic residues
responsible for their oligomerization (17–21 and 30–42 resi-
dues) and/or with residues in their vicinity by exploiting the
same interactions as in the Ab(1–42) assembly. A conformational
tightened state is produced by the interplay of ionic and
hydrophobic groups of both peptide and the conjugates.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineFerra˜o-Gonzales et al. showed that (1-anilino-8-naphthalene
sulfonate)-derivedmolecules inhibit Ab aggregation due to their
dual nature provided by hydrophobic regions and charged
groups.35 Vieira et al. demonstrated the eﬀectiveness of diﬀerent
uorinated alcohols in the b-to-a refolding process of Ab(1–40).14
The observed eﬀect was interpreted as a result of alteration of
the hydration shell of the peptides and hydrophobic eﬀects of
uorine groups. Montserret et al. have shown that although the
folding of amphipathic a-helical peptides in hydrophilic SDS
micellar solutions is mostly driven by electrostatic interactions,
when hydrophobic peptides are considered, SDS–peptide
hydrophobic interactions might be suﬃciently strong to induce
a-helical-rich structures.36 The eﬀect of uorinated complexes
made of polyampholyte and the sodium salt of per-
uorododecanoic acid on Ab was attributed to the hydrophobic
and acidic characters of the peruorododecanoic acid.18,19 We
propose that LVFfFD–PEG and LVfFFD–PEG have the necessary
hydrophobicity and spatial geometry to allow the interaction
with Ab(1–42). LPfFFD–PEG, with one uorine atom in the proline
residue, was not able to prevent Ab–Ab interactions. Proline
residues are generally solvent-exposed in proteins and they are
considered binding motifs in protein–protein interactions.37
However it is possible that the presence of the uorine atom in
the proline residue of the LPfFFD–PEG prevents the exposure of
the conjugate amino acids to Ab. Comparing the LPfFFD–PEG
with the non-uorinated analogue, one can assume that the
uorine atom increases the steric hindrance of the conjugate
reducing the access to the proline residue. On the other hand
the hydrophobic interactions between LPfFFD–PEG and Ab are
probably not strong enough when compared to the Ab–Ab
interactions. Apart from the apparently reduced interactions
between Ab and LPfFFD–PEG, the position of uorine atoms at
the extremity of the conjugate and the uorination of hydro-
phobic residues seem to favour the inhibitory eﬀect of the
sequences on Ab amyloid bril formation.
Conclusions
The eﬀects of uorinated alcohols, molecules or particles on Ab
bril formation are typically very diﬀerent from those of their
hydrogenated analogues. In general, it is possible to modify
hydrogenated molecules or particles with uorine atoms in
such a way that they would be able to induce an a-helix structure
on Ab, a conformation which is less prone to aggregation.
However, uorination of molecules does not always lead to the
inhibition of amyloid bril formation but it can instead
promote it. Therefore, it is important to understand the inter-
actions of uorinated molecules with Ab peptide. We propose
the use of beta-sheet breaker peptides as model molecules to
study the eﬀect of uorination on the Ab aggregation. There-
fore, sequences that play an important role in Ab amyloid bril
formation were modied with uorine atoms. Our work shows
that uorination of hydrophobic amino acids such as valine or
phenylalanine of sequences that interfere with amyloid bril
formation induces a signicant delay in the Ab aggregation
process. This eﬀect is likely a result of the interaction between
the uorinated amino acids and the hydrophobic residues ofThis journal is © The Royal Society of Chemistry 2014Ab, which is strong enough to prevent the contact between Ab
molecules and thus it prevents the peptide aggregation. The
uorination of other amino acids or the modication of the
uorinated sequences with hydrophilic residues at diﬀerent
positions will contribute to better understand the interactions
between Ab and uorinated peptides.
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